Navigation Links
Jeffrey Zucker of Worldwide Clinical Trials to Present at SCOPE 2016

MIAMI, February 11, 2016 /PRNewswire/ --

Jeffrey Zucker, vice president of Feasibility and Recruitment Optimization at Worldwide Clinical Trials, will present at this year's Summit for Clinical Operations Executives (SCOPE), being held Feb. 23-25 at the Hyatt Regency in Miami, FL. Zucker will discuss how sponsors can rebuild and enhance site partnerships to optimize study execution, supporting SCOPE's "Improving Site Study Activation and Performance" portion of the conference. His presentation will take place on Thursday, Feb. 25 at 11:05 a.m.

In addition to Zucker's presentation, experts from the Worldwide Clinical Trials team will also be on-hand at the company's booth (#311) to discuss the individual drug development challenges of SCOPE attendees, as well as their concerns and needs across a range of therapeutic areas, including neuroscience, cardiovascular disease, inflammatory disorders, and rare disease.

"The strategic balance of science, medicine and operations provides the foundation for successful execution of clinical trials," explains Zucker, who has more than 20 years of experience in clinical research operations. "While there are many challenges in trial planning and execution, during my presentation at SCOPE, I will explore how the relationship between the sponsor and the clinical trial site can have a significant impact on the efficiency and overall success of a clinical trial. From trial start-up and recruitment through implementation, I will offer strategies for establishing and maintaining key relationships, while defining the impact of a strong partnership."

The seventh annual SCOPE Summit will offer three days of discussions, conferences and workshops covering all aspects of clinical trial planning and management. To schedule an appointment with a Worldwide expert at SCOPE, visit . For further information about SCOPE, visit

About Worldwide Clinical Trials  

Worldwide Clinical Trials provides full-service drug development services to the pharmaceutical and biotechnology industries from Early Phase and Bioanalytical Sciences through Phase II and III trials to Peri-Approval studies. We believe successful drug development strategically balances science, medicine, operations and commercial intelligence. We approach every Phase I-IV drug development program as unique. Our mission is to foster the development of life changing medicines by integrating innovative methodology, rigorous science and efficient technology. For more information, visit

SOURCE Worldwide Clinical Trials
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Expands its Executive Management Team with Appointment of Dr. Jeffrey Su as Chief Operating Officer to Lead its in-house Bioprocess and Manufacturing Operations
2. Halozyme Appoints Jeffrey W. Henderson To Board
3. Landauer, Inc. Appoints Jeffrey Bailey As Independent Director
4. Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors
5. Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals
6. Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer
7. Texas Childrens Hospital establishes the Jeffrey Modell Diagnostic & Research Center with a donation from the Jeffrey Modell Foundation
8. Worldwide Clinical Trials Expert to Present at Evidence EU 2016
9. Radiology Oncology Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide, 2016-2022
10. Merck, Pfizer and AstraZeneca Emerge as Leaders in the 2016 Indegene Worldwide Digital Savvy HCP Study
11. California Institute for Biomedical Research (Calibr) enters worldwide strategic collaboration with Pfizer Inc.
Post Your Comments:
(Date:9/18/2019)... ... September 18, 2019 , ... NDA Partners Chairman ... well-respected preclinical drug development expert with a focus in the cardiovascular and metabolic ... to joining NDA Partners, Dr. Hoffmann served as Executive Director of Preclinical Safety ...
(Date:9/17/2019)... New Zealand (PRWEB) , ... September 17, 2019 , ... ... in in Fast Company’s 2019 Innovation by Design Awards Students category. , It was ... at the Auckland Bioengineering Institute. , Muss-Bits is comprised of two parts. A “sensor ...
(Date:9/17/2019)... ... 2019 , ... Scientists writing in a 2017 issue of ... progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” ... orthopedic surgeon Alejandro Badia, MD , founder and chief medical officer of ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... 17, 2019 , ... Caravan Health is seeking ... the country, the company announced today. High-performing community health systems and providers can ... cost efficiency. This opportunity is open to those new to value-based Medicare payment ...
(Date:9/17/2019)... PASO ROBLES, Calif. (PRWEB) , ... September 17, ... ... Pismo Beach , CA, recently announced that he has been certified by the ... Botox in dentistry is used to correct a wide range of orofacial conditions ...
(Date:9/17/2019)... BOSTON (PRWEB) , ... September 17, 2019 , ... ... Participation (CISCRP) is pleased to announce the release of the third edition of ... a comprehensive, easy-to-read guide for patients, caregivers and families to navigate the clinical ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... detection and treatment of infectious diseases at its annual Congress (WMIC) recently ... detection of residual HIV infected cell persistence and the development of pathogen-specific ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful ... coronary artery disease as he hopes to prevent anyone from having it and to ... author John Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to ...
Breaking Medicine News(10 mins):